AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graybill, J. R.
Right arrow Articles by Regen, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graybill, J. R.
Right arrow Articles by Regen, S. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1998, p. 147-150, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

KY-62, a Polyene Analog of Amphotericin B, for Treatment of Murine Candidiasis

John R. Graybill,1,2,* Laura K. Najvar,2 Annette Fothergill,2 Thomas Hardin,2 Michael Rinaldi,1,2 Chris Lambros,3 and Steven L. Regen4

University of Texas Health Science Center1 and South Texas Veterans Health Care System,2 San Antonio, Texas 78284; Lehigh University, Bethlehem, Pennsylvania 180153; and National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 208924

Received 14 July 1997/Returned for modification 21 August 1997/Accepted 16 October 1997

KY-62 is a water-soluble analog of amphotericin B. In vitro testing of five clinical isolates of Candida albicans showed KY-62 to have potency similar to that of amphotericin B. KY-62 was administered to mice infected intravenously with C. albicans. In vivo, KY-62 was effective in immunocompetent mice, with potency similar to that of amphotericin B. KY-62 was well tolerated up to 30 mg/kg of body weight per dose, an amount that would be lethal with amphotericin B. KY-62 was less effective in mice rendered neutropenic with 5-fluorouracil. The addition of flucytosine had little effect. KY-62 may have potential for clinical development.

* Corresponding author. Mailing address: Division of Infectious Diseases (111F), Audie L. Murphy Veterans Hospital, 7400 Merton Minter Blvd., San Antonio, TX 78284. Phone: (210) 617-5111. Fax: (210) 614-6197. E-mail: graybill{at}uthscsa.edu.

Antimicrobial Agents and Chemotherapy, January 1998, p. 147-150, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.